SCHEMBL23313201

SCHEMBL23313201

OC[C@H]1O[C@@H](n2cc(Cl)c3c(Cl)ncnc32)[C@@H](F)[C@@H]1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADK P55263 12/20 0.64
▸ SLC29A1 Q99808 1/20 0.64
▸ PDE2A O00408 1/20 0.49
▸ ADORA3 P0DMS8 1/20 0.49
▸ ADORA2A P29274 1/20 0.49
▸ ADORA1 P30542 1/20 0.49
▸ ADRA1A P35348 1/20 0.49
▸ PDE4D Q08499 1/20 0.49
▸ PDE3A Q14432 1/20 0.49
▸ PRMT5 O14744 2/20 0.49
▸ METTL3 Q86U44 2/20 0.49
▸ DOT1L Q8TEK3 1/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ GALR3 O60755 1/20 0.47
▸ S1PR4 O95977 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ S1PR1 P21453 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23989132 0.90 ADK (0.62) ADKSLC29A1PDE2AADORA3ADORA2A
SCHEMBL25352927 0.90 ADK (0.62) ADKSLC29A1PDE2AADORA3ADORA2A
SCHEMBL30536337 0.90 ADK (0.62) ADKSLC29A1PDE2AADORA3ADORA2A
SCHEMBL29365731 0.89 METTL3 (0.60) ADKSLC29A1PDE2AADORA3ADORA2A
SCHEMBL28713523 0.89 METTL3 (0.60) ADKSLC29A1PDE2AADORA3ADORA2A
SCHEMBL25098367 0.80 ADORA3 (0.64) SLC29A1PDE2AADORA3ADORA2AADORA1
SCHEMBL10160128 0.80 ADK (0.75) ADKSLC29A1DOT1LNPC1GALR3
SCHEMBL10131227 0.80 ADK (0.75) ADKSLC29A1DOT1LNPC1GALR3
SCHEMBL314530 0.80 ADK (0.75) ADKSLC29A1DOT1LNPC1GALR3
SCHEMBL9850177 0.80 ADORA3 (0.64) SLC29A1PDE2AADORA3ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230027361-A1 METTL3 MODULATORS ACCENT THERAPEUTICS, INC. (US) 2023-01-26 — — US disclosed
US-20230027361-A1 METTL3 MODULATORS ACCENT THERAPEUTICS, INC. (US) 2023-01-26 — — US disclosed
CN-115298179-A METTL3 modulators 埃克森特治疗公司 2022-11-04 — — CN disclosed
EP-4048674-A2 METTL3 MODULATORS Accent Therapeutics, Inc. (US) 2022-08-31 — — EP disclosed
WO-2021079196-A9 METTL3 MODULATORS ACCENT THERAPEUTICS, INC (US) 2022-07-14 — — WO disclosed
WO-2021079196-A9 METTL3 MODULATORS ACCENT THERAPEUTICS, INC (US) 2022-07-14 — — WO disclosed
WO-2021079196-A2 METTL3 MODULATORS ACCENT THERAPEUTICS, INC (US) 2021-04-29 — — WO disclosed
WO-2021079196-A2 METTL3 MODULATORS ACCENT THERAPEUTICS, INC (US) 2021-04-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027361-A1 METTL3 MODULATORS METTL3, METTL16, METTL14 ADK 1474/4885SLC29A1 433/4885PDE2A 2119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback